Medication Assisted Treatments for Opiates, But What About Stimulants?
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.
At the end of this session, learners should be able to:
- Understand the evidence of CM (contingency management) for chronic stimulant use disorder
- Understand the evidence of MAT (medication assisted treatment) for chronic stimulant use disorder
Participation and Credit:
Learners must register to participate in and receive credit for this online educational activity. Read the target audience, learning objectives, and author disclosures. Study the educational content online and complete the activity evaluation. Your certificate will be available to you as a downloadable link. You may print the certificate, but you cannot alter it. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
Unlabeled Use Disclosure:
This activity will not include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), and the curriculum clearly indicates this fact.
This activity is supported by the California Academy of Family Physicians Foundation with a grant from the California Department of Healthcare Services.
There is no charge for this activity.
CAFP policy and California state law requires that each learning activity have elements of cultural and linguistic proficiency included in the content. The definition of cultural and linguistic competency is the ability and readiness of health care providers and health organizations to humbly and respectfully demonstrate, effectively communicate, and tailor delivery of care to patients with diverse values, beliefs, identities, and behaviors, in order to meet patients’ social, cultural, and linguistic needs as it relates to patient health. This activity meets these requirements.
CAFP policy and California state law requires that all CME activities comprising a patient care element include either (1) examples of how implicit bias affects perceptions and treatment decisions of physicians and surgeons, leading to disparities in health outcomes and/or (2) strategies to address how unintended biases in decision-making may contribute to health care disparities by shaping behavior and producing differences in medical treatment along lines of race, ethnicity, gender identity, sexual orientation, age, socioeconomic status, or other characteristics. This activity meets these requirements.
The California Academy of Family Physicians (CAFP) is committed to protecting the privacy of its members and customers. CAFP maintains safeguards to store and secure information it has about members and customers. The safeguards may be physical, electronic or procedural. For more information, contact email@example.com.
For questions regarding the content of this activity or for technical assistance, contact firstname.lastname@example.org.
The CAFP has made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education program. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the learner is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Approval of credit for this continuing education program does not imply endorsement by CAFP of any product or manufacturer identified.
Any medications or treatment methods suggested in this CME activity should not be used by the practitioner without evaluation of their patient's condition(s) and possible contraindication(s) or danger(s) of use of any specific medication.
© 2023 California Academy of Family Physicians. No part of this activity may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embedded in articles or reviews.
Physicians and clinical providers in Primary Care and Emergency Medicine interested in the strength of evidence for treatment modalities of chronic stimulant use disorders.
Allen Wang, MD, MPH
Emergency Medicine Physician at Kaiser Permanente Central Valley
Conflict of Interest Statements:
The Committee on Continuing Professional Development and CME will be responsible for mitigating any relevant financial relationships disclosed by an individual who may have influence on content, who have served as faculty, or who may produce CME/CPD content for the CAFP. Mitigation may include learner notification, peer review of content before presentation, requirement of EB-CME, changing topics, or even dismissing a potential faculty member.
It is the policy of the CAFP to ensure independence, balance, objectivity, scientific rigor, and integrity in all continuing education activities. All individuals with potential to influence the content of this program have submitted Disclosure of Interest declarations that have been reviewed according to policy. Learner notification of declarations is below. All individuals with relevant financial relationships with ineligible companies have been contacted by CAFP staff or CCPD members, and issues of conflict have been discussed and mitigated.
Allen Wang is a retail investor in two early-stage biopharmaceutical companies, Atossa Genetics and Tonix Therapeutics, unrelated to substance use disorders. These relevant financial relationships have been mitigated.
The following planners have no relevant financial relationships to disclose:
Shelly B. Rodrigues, MS, CAE, FACEHP, FAAMSE
1.00 AAFP Prescribed Credit
The AAFP has reviewed CRPC: Education to Improve Services to Patients with OUD/SUD, and deemed it acceptable for AAFP credit. Term of approval is from 08/24/2023 to 08/24/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This session, Medication Assisted Treatments for Opiates, But What About Stimulants?, is approved for 1.00 Enduring AAFP Prescribed credits.
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed credit, not as Category 1.
1.00 AMA PRA Category 1 Credit™
The California Academy of Family Physicians is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The California Academy of Family Physicians designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
1.00 AOA Category 2-A
The California Academy of Family Physicians is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. This activity is approved for 1.00 AOA Category 2-A credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity
- 1.00 AAFP Prescribed
- 1.00 AMA PRA Category 1 Credit™
- 1.00 AOA Category 2-A